



www.ICLabs.ca

Memo No. 2018-022
Date: 29-May-2018
Memo To: Clients
Re: **Follow-Up:** Broad Spectrum Drug Screen Revision

ICL Memo 2018-021 described a revision in the reporting format of LC-MS/MS drug analysis for specimens received at ICL as of June 4th, 2018.

It should also have been noted that there will be no revision in the reporting of Benzodiazepine Screen and Creatinine (urine) and that the revised standard list of reported drugs is not identical to the list contemplated for April 2nd, 2018.

In addition, the laboratory has decided to use the term “Positive” rather than “Detected”.

If you have further questions, please contact Client Care at (416) 422-3000 Ext. 300 or info@ICLabs.ca or you may contact me directly.

Shashank Tilak PhD, DCC
Laboratory & Scientific Director
(416) 422-3000 Ext. 221
ShashTilak@ICLabs.ca

Want to receive updates by e-mail? Please contact Client Care info@ICLabs.ca

ICL is the only Not-For-Profit dedicated broker of lab diagnostic tests in Canada

57 Gervais Drive, North York, ON M3C 1Z2

(416) 422-3000 Ext. 300 info@ICLabs.ca